The U.S. Treasuries remained slightly higher during Monday’s afternoon session amid a muted trading day that witnessed data of little economic significance. However, this week’s few auctions and gross domestic product (GDP) for the second quarter of this year, due on August 29 shall provide some direction to the debt market.
The yield on the benchmark 10-year Treasury yield remained tad down at 1.522 percent, the super-long 30-year bond yield lost a little over 1 basis point to 2.012 percent and the yield on the short-term 2-year suffered 2 basis points to 1.510 percent by 12:30GMT.
Risk-off sentiment prevailed in early trade, with European equity markets opening lower and Asian bourses losing ground in today’s session, following the latest tit-for-tat trade war escalation between the world’s two largest economies, Eurobank Economic Analysis & Financial Markets Research reported.
Meanwhile, the S&P 500 Futures traded tad 0.49 percent lower at 2,869.38 by 12:35GMT.


Gold Prices Fall Amid Rate Jitters; Copper Steady as China Stimulus Eyed
Best Gold Stocks to Buy Now: AABB, GOLD, GDX
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom
FxWirePro: Daily Commodity Tracker - 21st March, 2022
Thailand Inflation Remains Negative for 10th Straight Month in January
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 



